![conference banner](/images/conference-banner.jpeg)
摘要
沿着血管生成途径的配体和受体之间的相互作用的特异性阻断代表了增强功效以及减少化学疗法不良反应的有效方法。 在过去十年中,这种治疗策略在癌症治疗中的应用进展很快。 抗血管生成治疗是卵巢癌最有希望的靶向治疗。 在一线设置或疾病复发中,将贝伐珠单抗添加到常规化学疗法中,可以改善卵巢癌患者的总体存活(OS),至少在预后不良的一部分患者中。 在本文中,我们总结了卵巢癌中用于抗血管生成治疗的主要药物的公布数据。 我们将回顾现有药剂的分子机制,临床试验结果,并描述新药的发展。 还讨论了血管生成抑制剂的局限性和副作用。
关键词: 卵巢癌,分子靶向,抗血管生成剂,血管发生,癌症治疗,抑制剂。
Current Drug Targets
Title:Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Volume: 18 Issue: 10
关键词: 卵巢癌,分子靶向,抗血管生成剂,血管发生,癌症治疗,抑制剂。
摘要: Specific blocking of interactions between ligands and receptors along the angiogenic pathways represents an effective approach for enhancing the efficacy as well as reducing adverse effects of chemotherapy. Over the past decade, there was a rapid progression in the application of this therapeutic strategy in cancer treatment. Anti-angiogenic therapy is the most promising targeted therapy for ovarian cancer. The addition of bevacizumab to conventional chemotherapy, either in the first-line setting or at disease relapse, may improve overall survival (OS) of ovarian cancer patients, at least in a subset of patients with poor prognosis. In this article, we summarize published data on the major agents used for anti-angiogenic therapy in ovarian cancers. We will review the molecular mechanisms, results of clinical trial of existing agents and describe the development of new agents. The limitations and side effects of angiogenesis inhibitor are also discussed.
Export Options
About this article
Cite this article as:
Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170329095807
DOI https://dx.doi.org/10.2174/1389450118666170329095807 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Intercalators in Cancer Therapy: Organic and Inorganic Drugs and Their Spectroscopic Tools of Analysis
Mini-Reviews in Medicinal Chemistry Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets From Anti-infective Agents to Cancer Therapy: A Drug Repositioning Study Revealed a New Use for Nitrofuran Derivatives
Medicinal Chemistry PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Regulation of Adrenomedullin and its Family Peptide by RAMP System – Lessons from Genetically Engineered Mice
Current Protein & Peptide Science The Trend of Immunotherapy Combined with Nanomedicine
Current Medicinal Chemistry A Novel Fluorescence-Labeled Curcumin Conjugate: Synthesis, Evaluation and Imaging on Human Cell Lines
Current Pharmaceutical Design Synthesis and Antitumoral Evaluation of Benzyl (1S)-2-[2-(monosubstituted-benzylidene)hydrazino]-1-(hydroxymethyl)-2-oxoethylcarbamate
Letters in Drug Design & Discovery Applications of Molecular Imaging in Cancer Gene Therapy
Current Gene Therapy Suppression of Cancer Invasiveness by Dietary Compounds
Mini-Reviews in Medicinal Chemistry Osteoimmunology and Beyond
Current Medicinal Chemistry The Influence of Macrophages and the Tumor Microenvironment on Natural Killer Cells
Current Molecular Medicine Impact of Antihypertensive Drug Use on Bone Mineral Density and Osteoporotic Fracture - From an Epidemiological Perspective
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) New Antitumour Natural Products from Marine Red Algae: Covering the Period from 2003 to 2012
Mini-Reviews in Medicinal Chemistry Caspase-8 as a Regulator of Tumor Cell Motility
Current Molecular Medicine The Anti-Cancer Activity of Noscapine: A Review
Recent Patents on Anti-Cancer Drug Discovery Molecular Docking Analysis of Flavonoid Compounds with Matrix Metalloproteinase- 8 for the Identification of Potential Effective Inhibitors
Letters in Drug Design & Discovery Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry A Fast and Efficient Chemiluminescence Method for Determination and Pharmacokinetic Study of Paclitaxel in Rat Plasma
Current Pharmaceutical Analysis